Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.

ABSTRACT:

Importance

Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC).

Objective

To assess trends and disparities in next-generation sequencing (NGS) testing among patients with mPC and aUC.

Design, setting, and participants

This retrospective cohort study used an electronic health record-derived database to extract deidentified data of patients receiving care from US physician practices, hospital-affiliated clinics, and academic practices. Patients diagnosed with mPC or aUC between March 1, 2015, and December 31, 2022, were included.

Exposures

Social determinants of health evaluated by race and ethnicity, socioeconomic status (SES), r

SUBMITTER: Hage Chehade C 

PROVIDER: S-EPMC11258596 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature